Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 92 clinical trials
Shengxian Quyu Decoction in the Treatment of Heart Failure With Reduced Ejection Fraction

The purpose of this study is to conduct a multicenter, randomized clinical trial to evaluate the effect of "Shengxian Quyu Decoction" on quality of life , symptoms, and biomarkers in heart failure patients with reduced ejection fraction.

  • 06 Apr, 2023
Muscle Stimulation for Physical Function During Stem Cell Transplant

Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to exposures including Agent Orange and an increased percentage of patients of African American ethnicity. Hematologic transplantation (HCT) is a common treatment for these cancers, but often …

  • 09 Apr, 2023
  • 1 location
Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION)

Digoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the early nineties revealed a highly significant reduction in HF hospitalizations, but no effect on mortality. A post-hoc analysis of the DIG trial suggests that low serum …

b-type natriuretic peptide
heart failure
chronic heart failure
  • 16 Mar, 2022
  • 36 locations
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction

  • 04 Apr, 2023
  • 47 locations
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) (DANHEART)

The present study is testing in a combined design to types of drugs in patients with chronic heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2) Metformin

beta blockers
oral glucose tolerance test
heart failure
aldosterone antagonists
  • 23 Oct, 2022
  • 23 locations
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF) (CARDINAL-HF)

This is a two-part study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo …

ejection fraction
heart failure
  • 14 Oct, 2022
  • 18 locations
Fluid Restriction in Heart Failure Versus Liberal Fluid Uptake (FRESH-UP)

Multi-centre open-label 1:1 randomized clinical trial in chronic heart failure patients on the effect of fluid restriction versus liberal fluid intake on quality of life.

heart failure
chronic heart failure
  • 04 Oct, 2022
  • 4 locations
A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation

) Functional Class II to Class IV chronic heart failure.

blood pool scan
functional mitral regurgitation
heart failure
  • 30 Jun, 2021
  • 28 locations
PVP-Guided Decongestive Therapy in HF (PERIPHERAL-HF)

The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.

heart failure
diuretic therapy
chronic heart failure
  • 07 Apr, 2023
  • 2 locations
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO)

Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for provoked VTE. Purpose: To establish the safety and efficacy of low-intensity apixaban versus placebo for extended prevention of recurrence after provoked VTE in patients with at …

apixaban 2.5 mg
myocardial infarction
heart failure
  • 04 Oct, 2022
  • 1 location